BioSpace News Archive

Artificial Intelligence in Digital Genome Market Detailed Analysis and Forecast to 2030

The artificial intelligence in digital genome market has been projected to experience noticeable growth avenues in the following years.

January 6, 2022
·
4 min read
Anti-Snoring Devices and Snoring Surgery Market Opportunity Assessment and Forecast up to 2024

The global anti snoring devices and snoring surgery market depicts a fragmented competitive landscape.

January 6, 2022
·
4 min read
Addiction Treatment Market Outlook, Opportunity and Demand Analysis, Forecast 2020 - 2030

According to the report, the global addiction treatment market was valued at ~US$ 6 Bn in 2019 and is projected to expand at a CAGR of ~6% from 2020 to 2030.

January 6, 2022
·
6 min read
Photocure to Present at the H.C. Wainwright BioConnect 2022 Virtual Conference

Photocure ASA announces that President and Chief Executive Officer, Dan Schneider and Chief Financial Officer, Erik Dahl are scheduled to present a corporate overview and participate in meetings with investors at the H.C. Wainwright BioConnect 2022 Virtual Conference to be held January 10-13, 2022.

January 6, 2022
·
2 min read
Basilea reports on portfolio progress made in 2021

Basilea Pharmaceutica Ltd., a commercial-stage biopharmaceutical company committed to meeting the needs of patients with infectious diseases and cancer, provided an update on the progress made with both its commercial brands and in its key research and development programs in 2021.

January 6, 2022
·
8 min read
Deals

Nuance Pharma acquires Sino Health to further strengthen its commercial capabilities and expand pipelines

Nuance Pharma announced an agreement with Sino Health Pharmaceutical Limited, an affiliated company of Yinglian Pharmaceutical Holdings Group Limited, to fully acquire its 100-percent equity shares and its fully-owned subsidiaries Ying Lian Zhuhai and Ying Lian Germany.

January 6, 2022
·
3 min read
Policy

China NMPA Approves Tislelizumab as Second- or Third-Line Treatment for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer

BeiGene announced that the China National Medical Products Administration has approved BeiGene’s anti-PD-1 antibody tislelizumab as a second- or third-line treatment for patients with locally advanced or metastatic non-small cell lung cancer.

January 6, 2022
·
14 min read
Biotech Beach

ONK Therapeutics Announces $21.5M Series A Financing to Advance Pipeline of Next-Generation Optimally Engineered Off-the-Shelf NK Cell Therapies

ONK Therapeutics, an innovative NK cell therapy platform company, announced the closing of its $21.5 million Series A financing, led by current investors Acorn Bioventures and ALSHC, who were joined by Cormorant Asset Management.

January 6, 2022
·
6 min read
Business

Samsara Therapeutics Establishes Scientific Advisory Board

Samsara Therapeutics Inc. announced the formation of its scientific advisory board with the appointment of four distinguished leaders in the areas of neurodegeneration, rare genetic disease, and protein sciences.

January 6, 2022
·
4 min read
Business

Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

Notable Labs, Inc., a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., MBA, as Chief Business Officer.

January 6, 2022
·
3 min read